Skip to main content

Main menu

  • Home
  • Content
    • Latest
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Alerts
    • Feedback
    • Folders
    • Help
  • Other Publications
    • Saudi Medical Journal

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Neurosciences Journal
  • Other Publications
    • Saudi Medical Journal
  • My alerts
  • Log in
Neurosciences Journal

Advanced Search

  • Home
  • Content
    • Latest
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Alerts
    • Feedback
    • Folders
    • Help
  • Follow psmmc on Twitter
  • Visit psmmc on Facebook
  • RSS
Research ArticleOriginal Article
Open Access

COMTVal158Met polymorphism is associated with ecstasy (MDMA)-induced psychotic symptoms in the Turkish population

Hasan Mervan Aytac, Yasemin Oyaci, Pinar Cetinay Aydin, Mustafa Pehlivan and Sacide Pehlivan
Neurosciences Journal January 2022, 27 (1) 24-30; DOI: https://doi.org/10.17712/nsj.2022.1.20210045
Hasan Mervan Aytac
From the Department of Psychiatry (Aytac), Basaksehir Cam and Sakura City Hospital; Department of Medical Biology (Oyaci, Pehlivan), Istanbul Faculty of Medicine, Istanbul University, and from the Department of Psychiatry (Cetinay Aydin), Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Psychiatry Clinic, University of Health Sciences, Istanbul, and from the Department of Hematology (Pehlivan), Gaziantep University, Faculty of Medicine, Gaziantep, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Yasemin Oyaci
From the Department of Psychiatry (Aytac), Basaksehir Cam and Sakura City Hospital; Department of Medical Biology (Oyaci, Pehlivan), Istanbul Faculty of Medicine, Istanbul University, and from the Department of Psychiatry (Cetinay Aydin), Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Psychiatry Clinic, University of Health Sciences, Istanbul, and from the Department of Hematology (Pehlivan), Gaziantep University, Faculty of Medicine, Gaziantep, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pinar Cetinay Aydin
From the Department of Psychiatry (Aytac), Basaksehir Cam and Sakura City Hospital; Department of Medical Biology (Oyaci, Pehlivan), Istanbul Faculty of Medicine, Istanbul University, and from the Department of Psychiatry (Cetinay Aydin), Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Psychiatry Clinic, University of Health Sciences, Istanbul, and from the Department of Hematology (Pehlivan), Gaziantep University, Faculty of Medicine, Gaziantep, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mustafa Pehlivan
From the Department of Psychiatry (Aytac), Basaksehir Cam and Sakura City Hospital; Department of Medical Biology (Oyaci, Pehlivan), Istanbul Faculty of Medicine, Istanbul University, and from the Department of Psychiatry (Cetinay Aydin), Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Psychiatry Clinic, University of Health Sciences, Istanbul, and from the Department of Hematology (Pehlivan), Gaziantep University, Faculty of Medicine, Gaziantep, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sacide Pehlivan
From the Department of Psychiatry (Aytac), Basaksehir Cam and Sakura City Hospital; Department of Medical Biology (Oyaci, Pehlivan), Istanbul Faculty of Medicine, Istanbul University, and from the Department of Psychiatry (Cetinay Aydin), Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Psychiatry Clinic, University of Health Sciences, Istanbul, and from the Department of Hematology (Pehlivan), Gaziantep University, Faculty of Medicine, Gaziantep, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • References
  • PDF
Loading

References

  1. 1.↵
    1. Karlsen SN,
    2. Spigset O,
    3. Slørdal L
    . The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3, 4-methylenedioxymethamphetamine. Basic & clinical pharmacology & toxicology 2008; 102: 15–24.
    OpenUrl
  2. 2.↵
    1. Han DD,
    2. Gu HH
    . Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC pharmacology 2006; 6: 1–7.
    OpenUrl
  3. 3.↵
    1. Quinton MS,
    2. Yamamoto BK
    . Causes and consequences of methamphetamine and MDMA toxicity. AAPS J 2006; 8: E337–E347.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Virani S,
    2. Daya GN,
    3. Brainch N,
    4. Kotapati VP,
    5. Zaveri D,
    6. Ahmed S
    . Persistent Psychosis due to Single Dose of Ecstasy. Cureus 2018; 10: e3058.
    OpenUrl
  5. 5.↵
    1. Potash MN,
    2. Gordon KA,
    3. Conrad KL
    . Persistent psychosis and medical complications after a single ingestion of MDMA “Ecstasy”: a case report and review of the literature. Psychiatry (Edgmont) 2009; 6: 40–44.
    OpenUrlPubMed
  6. 6.↵
    1. Chen J,
    2. Lipska BK,
    3. Halim N,
    4. Ma QD,
    5. Matsumoto M,
    6. Melhem S, et al.
    Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004; 75: 807–821.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Lachman HM
    . Does COMT val158met affect behavioral phenotypes: yes, no, maybe? Neuropsychopharmacology 2008; 33: 3027–3029.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Hosák L
    . Role of the COMT gene Val158Met polymorphism in mental disorders: a review. Eur Psychiatry 2007; 22: 276–281.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.
    1. Oyaci Y,
    2. Aytac HM,
    3. Pasin O,
    4. Cetinay Aydin P,
    5. Pehlivan S
    . Detection of altered methylation of MB-COMT promotor and DRD2 gene in cannabinoid or synthetic cannabinoid use disorder regarding gene variants and clinical parameters. J Addict Dis 2021; 1–19.
  10. 10.↵
    1. Pehlivan S,
    2. Aydin PÇ,
    3. Aytaç HM,
    4. Uysal MA,
    5. Sever Ü,
    6. Pehlivan M
    . Investigation of Catechol-O-Methyltransferase and Cannabinoid Receptor 2 gene variants in tobacco use disorder or tobacco use disorder and schizophrenia comorbidity. Anatolian Journal of Psychiatry 2020; 21: 572–578.
    OpenUrl
  11. 11.↵
    1. Kirov G,
    2. Murphy K,
    3. Arranz M,
    4. Jones I,
    5. McCandles F,
    6. Kunugi H, et al.
    Low activity allele of catechol-O-methyltransferase gene associated with rapid cycling bipolar disorder. Mol Psychiatry 1998; 3: 342–345.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Strous RD,
    2. Nolan KA,
    3. Lapidus R,
    4. Diaz L,
    5. Saito T,
    6. Lachman HM
    . Aggressive behavior in schizophrenia is associated with the low enzyme activity COMT polymorphism: a replication study. Am J Med Genet B Neuropsychiatr Genet 2003; 120B: 29–34.
    OpenUrl
  13. 13.↵
    1. Pehlivan S,
    2. Aytac HM,
    3. Kurnaz S,
    4. Pehlivan M,
    5. Cetinay Aydin P
    . Evaluation of COMT (rs4680), CNR2 (rs2501432), CNR2 (rs2229579), UCP2 (rs659366), and IL-17 (rs763780) gene variants in synthetic cannabinoid use disorder patients. Journal of Addictive Diseases 2020: 1–11.
  14. 14.
    1. Tammimäki AE,
    2. Männistö PT
    . Are genetic variants of COMT associated with addiction? Pharmacogenet Genomics 2010; 20: 717–741.
    OpenUrlPubMedWeb of Science
  15. 15.↵
    1. Jugurnauth SK,
    2. Chen CK,
    3. Barnes MR,
    4. Li T,
    5. Lin SK,
    6. Liu HC, et al.
    A COMT gene haplotype associated with methamphetamine abuse. Pharmacogenet Genomics 2011; 21: 731–740.
    OpenUrlPubMed
  16. 16.↵
    1. Association WM
    . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191–2194.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Baclig MO,
    2. Predicala RZ,
    3. Mapua CA,
    4. Lozano-Kühne JP,
    5. Daroy MLG,
    6. Natividad FF, et al.
    Allelic and genotype frequencies of catechol-O-methyltransferase (Val158Met) and CYP2D6* 10 (Pro34Ser) single nucleotide polymorphisms in the Philippines. Int J Mol Epidemiol Genet 2012; 3: 115–121.
    OpenUrlPubMed
  18. 18.↵
    1. Lee W-C,
    2. Wang L-Y
    . Simple formulas for gauging the potential impacts of population stratification bias. Am J Epidemiol 2008; 167: 86–89.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Lohoff FW,
    2. Weller AE,
    3. Bloch PJ,
    4. Nall AH,
    5. Ferraro TN,
    6. Kampman KM, et al.
    Association between the catechol-O-methyltransferase Val158Met polymorphism and cocaine dependence. Neuropsychopharmacology 2008; 33: 3078–3084.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Mizuno Y,
    2. Jung M,
    3. Fujisawa TX,
    4. Takiguchi S,
    5. Shimada K,
    6. Saito DN, et al.
    Catechol-O-methyltransferase polymorphism is associated with the cortico-cerebellar functional connectivity of executive function in children with attention-deficit/hyperactivity disorder. Sci Rep 2017; 7: 4850.
    OpenUrl
  21. 21.↵
    1. Hosák L
    . Role of the COMT gene Val158Met polymorphism in mental disorders: a review. Eur Psychiatry 2007; 22: 276–281.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Schilt T,
    2. Koeter MW,
    3. de Win MM,
    4. Zinkstok JR,
    5. van Amelsvoort TA,
    6. Schmand B, et al.
    The effect of Ecstasy on memory is moderated by a functional polymorphism in the cathechol-O-methyltransferase (COMT) gene. Eur Neuropsychopharmacol 2009; 19: 116–124.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Fagundo AB,
    2. Cuyàs E,
    3. Verdejo-Garcia A,
    4. Khymenets O,
    5. Langohr K,
    6. Martín-Santos R, et al.
    The influence of 5-HTT and COMT genotypes on verbal fluency in ecstasy users. J Psychopharmacol 2010; 24: 1381–1393.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Li T,
    2. Chen Ck,
    3. Hu X,
    4. Ball D,
    5. Lin SK,
    6. Chen W, et al.
    Association analysis of the DRD4 and COMT genes in methamphetamine abuse. Am J Med Genet B Neuropsychiatr Genet 2004; 129B: 120–124.
    OpenUrl
  25. 25.↵
    1. Taylor S
    . Association between COMT Val158Met and psychiatric disorders: A comprehensive meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2018; 177: 199–210.
    OpenUrl
  26. 26.↵
    1. Hosak L,
    2. Libiger J,
    3. Cizek L,
    4. Beranek M,
    5. Cermakova E
    . The COMT Val158Met polymorphism is associated with novelty seeking in Czech methamphetamine abusers: preliminary results. Neuro Endocrinol Lett 2006; 27: 799–802.
    OpenUrlPubMed
  27. 27.↵
    1. Bousman C,
    2. Cherner M,
    3. Atkinson J,
    4. Heaton R,
    5. Grant I,
    6. Everall I, et al.
    COMT Val158Met polymorphism, executive dysfunction, and sexual risk behavior in the context of HIV infection and methamphetamine dependence. Interdiscip Perspect Infect Dis 2010; 2010: 678648.
    OpenUrlPubMed
  28. 28.↵
    1. Suzuki A,
    2. Nakamura K,
    3. Sekine Y,
    4. Minabe Y,
    5. Takei N,
    6. Suzuki K, et al.
    An association study between catechol-O-methyl transferase gene polymorphism and methamphetamine psychotic disorder. Psychiatr Genet 2006; 16: 133–138.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Egan MF,
    2. Goldberg TE,
    3. Kolachana BS,
    4. Callicott JH,
    5. Mazzanti CM,
    6. Straub RE, et al.
    Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001; 98: 6917–6922.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Mattay VS,
    2. Goldberg TE,
    3. Fera F,
    4. Hariri AR,
    5. Tessitore A,
    6. Egan MF, et al.
    Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 2003; 100: 6186–6191.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Sara GE,
    2. Large MM,
    3. Matheson SL,
    4. Burgess PM,
    5. Malhi GS,
    6. Whiteford HA, et al.
    Stimulant use disorders in people with psychosis: a meta-analysis of rate and factors affecting variation. Aust N Z J Psychiatry 2015; 49: 106–117.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. McKetin R,
    2. McLaren J,
    3. Lubman DI,
    4. Hides L
    . The prevalence of psychotic symptoms among methamphetamine users. Addiction 2006; 101: 1473–1478.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    1. Curran C,
    2. Byrappa N,
    3. McBride A
    . Stimulant psychosis: systematic review. Br J Psychiatry 2004; 185: 196–204.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Virani S,
    2. Daya GN,
    3. Brainch N,
    4. Kotapati VP,
    5. Zaveri D,
    6. Ahmed S
    . Persistent Psychosis due to Single Dose of Ecstasy. Cureus 2018; 10: e3058.
    OpenUrl
  35. 35.↵
    1. Duman B,
    2. Sedes N,
    3. Baskak B
    . Additive Effects of Former Methylenedioxymethamphetamine and Cannabis Use on Subclinical Psychotic Symptoms. Noro Psikiyatr Ars 2017; 54: 38–42.
    OpenUrl
  36. 36.↵
    1. Hosák L,
    2. Serý O,
    3. Beranek M,
    4. Alda M
    . Lack of association between the Val158Met catechol-O-methyltransferase gene polymorphism and methamphetamine dependence. Neuro Endocrinol Lett 2011; 32: 469–474.
    OpenUrlPubMed
  37. 37.↵
    1. Zumárraga M,
    2. Arrúe A,
    3. Basterreche N,
    4. Macías I,
    5. Catalán A,
    6. Madrazo A, et al.
    COMT haplotypes, catecholamine metabolites in plasma and clinical response in schizophrenic and bipolar patients. Pharmacogenomics 2016; 17: 837–851.
    OpenUrl
  38. 38.↵
    1. Meyer-Lindenberg A,
    2. Kohn PD,
    3. Kolachana B,
    4. Kippenhan S,
    5. McInerney-Leo A,
    6. Nussbaum R, et al.
    Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci 2005; 8: 594–596.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Tunbridge EM,
    2. Harrison PJ,
    3. Weinberger DR
    . Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 2006; 60: 141–151.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Gouzoulis-Mayfrank E,
    2. Daumann J
    . Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction 2006; 101: 348–361.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Kanthasamy A,
    2. Sprague J,
    3. Shotwell J,
    4. Nichols D
    . Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum. Neuroscience 2002; 114: 917–924.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top

In this issue

Neurosciences Journal: 27 (1)
Neurosciences Journal
Vol. 27, Issue 1
1 Jan 2022
  • Table of Contents
  • Cover (PDF)
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Neurosciences Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
COMTVal158Met polymorphism is associated with ecstasy (MDMA)-induced psychotic symptoms in the Turkish population
(Your Name) has sent you a message from Neurosciences Journal
(Your Name) thought you would like to see the Neurosciences Journal web site.
Citation Tools
COMTVal158Met polymorphism is associated with ecstasy (MDMA)-induced psychotic symptoms in the Turkish population
Hasan Mervan Aytac, Yasemin Oyaci, Pinar Cetinay Aydin, Mustafa Pehlivan, Sacide Pehlivan
Neurosciences Journal Jan 2022, 27 (1) 24-30; DOI: 10.17712/nsj.2022.1.20210045

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
COMTVal158Met polymorphism is associated with ecstasy (MDMA)-induced psychotic symptoms in the Turkish population
Hasan Mervan Aytac, Yasemin Oyaci, Pinar Cetinay Aydin, Mustafa Pehlivan, Sacide Pehlivan
Neurosciences Journal Jan 2022, 27 (1) 24-30; DOI: 10.17712/nsj.2022.1.20210045
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgement
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Prevalence of depressive symptoms and its correlates in primary headache patients with a history of head-neck trauma
  • Effect of COVID-19 pandemic on hospital admission rates of patients with malnutrition and/or neuromuscular complications after bariatric surgery
  • Paradigm shift in migraine management impacted by COVID-19 pandemic and the role of confounding factors inflicting the change
Show more Original Article

Similar Articles

Navigate

  • home

More Information

  • Help

Additional journals

  • All Topics

Other Services

  • About

© 2022 Neurosciences Journal Neurosciences is copyright under the Berne Convention and the International Copyright Convention. All rights reserved. Neurosciences is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work. Electronic ISSN 1658-3183. Print ISSN 1319-6138.

Powered by HighWire